📊 ACAT Key Takeaways
Is NP Life Sciences Health Industry Group Inc. (ACAT) a Good Investment?
NP Life Sciences is a pre-revenue/minimal-revenue educational services company with severely negative profitability, burning cash at an unsustainable rate ($73.6K operating cash outflow against only $164.6K revenue). Despite adequate short-term liquidity, the company's persistent operating losses, negative ROE/ROA, and deteriorating financial position indicate fundamental business dysfunction with no clear path to profitability.
NP Life Sciences Health Industry Group shows modest top-line growth, but the quality of that growth is weak because revenue remains extremely small and cash generation is deeply negative. Despite a clean balance sheet and strong near-term liquidity, persistent losses, negative returns on assets and equity, and operating cash burn suggest an unstable fundamental base.
Why Buy NP Life Sciences Health Industry Group Inc. Stock? ACAT Key Strengths
- Strong short-term liquidity with 7.31x current ratio and $70.6K cash position
- Minimal debt burden with 0x debt-to-equity ratio reducing solvency risk
- Revenue growth of 13.8% YoY showing some top-line traction
- Revenue grew 13.8% year over year, indicating some top-line momentum
- Cash of $70.61K supports a strong current and quick ratio of 7.31x
- No meaningful debt leverage, reducing balance sheet strain
ACAT Stock Risks: NP Life Sciences Health Industry Group Inc. Investment Risks
- Operating cash burn of $73.6K annually is unsustainable given only $164.6K revenue; cash runway critically limited
- Negative operating margin (-0.4%), net margin (-1.8%), ROE (-17.9%), and ROA (-3.8%) indicate severe operational dysfunction
- Microscopic revenue base ($164.6K) with negative net income suggests company lacks viable business model or meaningful customer adoption
- Operating cash flow and free cash flow are sharply negative at -$73.61K, far worse than reported net loss
- Business scale is very small, with only $164.62K in revenue and limited equity cushion of $16.38K
- Profitability remains weak with negative operating margin, negative ROE, and negative ROA
Key Metrics to Watch
- Operating cash flow trend - critical to assess sustainability; current burn rate is terminal
- Revenue trajectory and customer acquisition cost relative to sales - currently insufficient to cover operating expenses
- Path to GAAP profitability and operating margin expansion - no evidence of viable scaling model
- Operating cash flow relative to revenue
- Sustainable improvement in net margin and equity base
NP Life Sciences Health Industry Group Inc. (ACAT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.31x current ratio provides a solid financial cushion.
ACAT Profit Margin, ROE & Profitability Analysis
ACAT vs Services Sector: How NP Life Sciences Health Industry Group Inc. Compares
How NP Life Sciences Health Industry Group Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NP Life Sciences Health Industry Group Inc. Stock Overvalued? ACAT Valuation Analysis 2026
Based on fundamental analysis, NP Life Sciences Health Industry Group Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NP Life Sciences Health Industry Group Inc. Balance Sheet: ACAT Debt, Cash & Liquidity
ACAT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NP Life Sciences Health Industry Group Inc.'s revenue has grown significantly by 283% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.
ACAT Revenue Growth, EPS Growth & YoY Performance
ACAT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $17.5K | -$5.4K | N/A |
| Q2 2023 | $15.0K | $1.1K | N/A |
| Q1 2023 | $30.0K | $1.2K | $0.00 |
| Q3 2022 | $41.0K | -$5.4K | N/A |
| Q2 2022 | $15.0K | $1.1K | N/A |
| Q3 2021 | $15.0K | -$20.8K | N/A |
| Q2 2021 | $15.0K | -$52.7K | N/A |
| Q1 2021 | $15.0K | -$24.2K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NP Life Sciences Health Industry Group Inc. Dividends, Buybacks & Capital Allocation
ACAT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NP Life Sciences Health Industry Group Inc. (CIK: 0001781726)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACAT
What is the AI rating for ACAT?
NP Life Sciences Health Industry Group Inc. (ACAT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACAT's key strengths?
Claude: Strong short-term liquidity with 7.31x current ratio and $70.6K cash position. Minimal debt burden with 0x debt-to-equity ratio reducing solvency risk. ChatGPT: Revenue grew 13.8% year over year, indicating some top-line momentum. Cash of $70.61K supports a strong current and quick ratio of 7.31x.
What are the risks of investing in ACAT?
Claude: Operating cash burn of $73.6K annually is unsustainable given only $164.6K revenue; cash runway critically limited. Negative operating margin (-0.4%), net margin (-1.8%), ROE (-17.9%), and ROA (-3.8%) indicate severe operational dysfunction. ChatGPT: Operating cash flow and free cash flow are sharply negative at -$73.61K, far worse than reported net loss. Business scale is very small, with only $164.62K in revenue and limited equity cushion of $16.38K.
What is ACAT's revenue and growth?
NP Life Sciences Health Industry Group Inc. reported revenue of $164.6K.
Does ACAT pay dividends?
NP Life Sciences Health Industry Group Inc. does not currently pay dividends.
Where can I find ACAT SEC filings?
Official SEC filings for NP Life Sciences Health Industry Group Inc. (CIK: 0001781726) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACAT's EPS?
NP Life Sciences Health Industry Group Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACAT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NP Life Sciences Health Industry Group Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACAT stock overvalued or undervalued?
Valuation metrics for ACAT: ROE of -17.9% (sector avg: 16%), net margin of -1.8% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy ACAT stock in 2026?
Our dual AI analysis gives NP Life Sciences Health Industry Group Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACAT's free cash flow?
NP Life Sciences Health Industry Group Inc.'s operating cash flow is $-73.6K, with capital expenditures of N/A. FCF margin is -44.7%.
How does ACAT compare to other Services stocks?
Vs Services sector averages: Net margin -1.8% (avg: 10%), ROE -17.9% (avg: 16%), current ratio 7.31 (avg: 1.5).